Novo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk

Dow Jones06-03

0948 GMT - Novo Nordisk's launch of its Wegovy pill in the UAE is an important milestone as the company takes its first step outside the U.S. with an oral version of its obesity treatment, says AJ Bell's Russ Mould. "A pill version is expected to broaden the market for Wegovy given the logistical advantages--it does not require cold-chain refrigeration like liquid injection pens--and the fact that some people would be more comfortable with a pill than a jab." This is in evidence in the U.S., where a pill was launched at the start of this year and has already seen healthy demand, Mould says. Novo Nordisk's main rival, Eli Lilly, announced the launch of its own pill in the UAE in April. Shares rise 0.1%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

June 03, 2026 05:48 ET (09:48 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640082379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640082379","market":"sh","top_or_hot":-1,"title":"Novo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0948 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s launch of its Wegovy pill in the UAE is an important milestone as the company takes its first step outside the U.S. with an oral version of its obesity treatment, says AJ Bell's Russ Mould. \"A pill version is expected to broaden the market for Wegovy given the logistical advantages--it does not require cold-chain refrigeration like liquid injection pens--and the fact that some people would be more comfortable with a pill than a jab.\" This is in evidence in the U.S., where a pill was launched at the start of this year and has already seen healthy demand, Mould says. Novo Nordisk's main rival, Eli Lilly, announced the launch of its own pill in the UAE in April. Shares rise 0.1%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 05:48 ET (09:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's UAE Wegovy Pill Launch an Important Step -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-03 17:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0948 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s launch of its Wegovy pill in the UAE is an important milestone as the company takes its first step outside the U.S. with an oral version of its obesity treatment, says AJ Bell's Russ Mould. \"A pill version is expected to broaden the market for Wegovy given the logistical advantages--it does not require cold-chain refrigeration like liquid injection pens--and the fact that some people would be more comfortable with a pill than a jab.\" This is in evidence in the U.S., where a pill was launched at the start of this year and has already seen healthy demand, Mould says. Novo Nordisk's main rival, Eli Lilly, announced the launch of its own pill in the UAE in April. Shares rise 0.1%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 05:48 ET (09:48 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756168.USD","symbol_name":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640082379","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640082379","pubTimestamp":1780480080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0948 GMT - Novo Nordisk's launch of its Wegovy pill in the UAE is an important milestone as the company takes its first step outside the U.S. with an oral version of its obesity treatment, says AJ Bell's Russ Mould. \"A pill version is expected to broaden the market for Wegovy given the logistical advantages--it does not require cold-chain refrigeration like liquid injection pens--and the fact that some people would be more comfortable with a pill than a jab.\" This is in evidence in the U.S., where a pill was launched at the start of this year and has already seen healthy demand, Mould says. Novo Nordisk's main rival, Eli Lilly, announced the launch of its own pill in the UAE in April. Shares rise 0.1%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4007":"制药","NVOX":"2倍做多NVO ETF-Defiance"},"translate_title":"诺和诺德在阿联酋推出Wegovy药丸迈出重要一步——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVO":1.95,"NVOH":0.6},"content_text":"0948 GMT - Novo Nordisk's launch of its Wegovy pill in the UAE is an important milestone as the company takes its first step outside the U.S. with an oral version of its obesity treatment, says AJ Bell's Russ Mould. \"A pill version is expected to broaden the market for Wegovy given the logistical advantages--it does not require cold-chain refrigeration like liquid injection pens--and the fact that some people would be more comfortable with a pill than a jab.\" This is in evidence in the U.S., where a pill was launched at the start of this year and has already seen healthy demand, Mould says. Novo Nordisk's main rival, Eli Lilly, announced the launch of its own pill in the UAE in April. Shares rise 0.1%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 05:48 ET (09:48 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640082379","isCrawlerRequest":true}